{"ModuleTitle": "Company Description", "CompanyName": "Arcturus Therapeutics Holdings Inc.", "Symbol": "ARCT", "Address": "10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, California, 92121, United States of America", "Phone": "(858) 900-2660", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "Middle East", "CompanyDescription": "We are a messenger RNA medicines company focused on significant opportunities\r\nwithin liver and respiratory rare diseases, and the development of infectious\r\ndisease vaccines utilizing our Self-Transcribing and Replicating RNA (\"STARR\")\r\ntechnology. In addition to our internal messenger RNA (\"mRNA\") platform, our\r\nproprietary lipid nanoparticle delivery system, LUNAR, has the potential to\r\nenable multiple nucleic acid medicines. \r\n\r\nOur company was founded in 2013 as Arcturus Therapeutics, Inc., and we have\r\nmaintained our principal executive offices in San Diego, California since that\r\ntime. In November 2017, Alcobra Ltd., an Israeli limited company, merged with\r\nour company, changed its name to Arcturus Therapeutics Ltd. (\"Arcturus Israel\"),\r\nand commenced trading on Nasdaq under the symbol \"ARCT.\" On June 17, 2019, we\r\nredomiciled to the United States (the \"Redomiciliation\") and changed our name to\r\nArcturus Therapeutics Holdings Inc., as described more fully below.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f16%2f0001564590-20-011037.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Andrew H. Sassine", "title": "Chief Financial Officer & Director"}, {"name": "Joseph E. Payne", "title": "President, Chief Executive Officer & Director"}, {"name": "Padmanabh Chivukula", "title": "Secretary, Chief Operating & Scientific Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}